•The FDA's Cellular, Tissue and Gene Therapies Advisory Committee voted that available evidence did not support the effectiveness of Deramiocel for DMD cardiomyopathy.
•The committee vote was 3 in favor and 9 against, noting that the committee's recommendation is non-binding for the FDA.
